secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001739104-24-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q3 revenue $1.03B, +1% organic; adj. EPS $0.13; 2024 guidance tightened
------------------------------------------------------------------------------

- Reported net income $364M ($0.73 EPS) includes $640M pre-tax gain from July aqua divestiture; adjusted net income $66M ($0.13 EPS).
- Full-year 2024 guidance tightened: revenue $4.42-$4.45B, adj. EBITDA $900-$930M, adj. EPS $0.89-$0.95 (midpoint unchanged).
- U.S. FDA approved Zenrelia (JAK inhibitor for atopic dermatitis in dogs) and Credelio Quattro (broad-spectrum parasiticide).
- Net leverage ratio 4.3x, down from 5.6x at June 30; aided by aqua divestiture proceeds and debt paydown.
- Pet health revenue $486M (-2% organic); Farm animal $530M (+3% organic); cattle up 6% on Experior and Rumensin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910424000036/0001739104-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910424000036/elan-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001739104-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer